Ke‐Neng Chen
Impact in
-
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Sarcoma Diagnosis and Treatment
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
Papers in
-
- Lung Cancer Diagnosis and Treatment 27
- Lung Cancer Treatments and Mutations 15
- Sarcoma Diagnosis and Treatment 5
- Neurology 20
- Myasthenia Gravis and Thymoma 20
- Co-authors
- Shugeng Gao (3 shared papers)Jonathan David Spicer (2 shared papers)Moïshe Liberman (2 shared papers)E. Eigendorff (1 shared paper)Jing Liang Yang (1 shared paper)Se‐Hoon Lee (1 shared paper)Jamie E. Chaft (1 shared paper)Steven M. Keller (1 shared paper)
- Journals
- Translational Lung Cancer Research (6 papers)Journal of Clinical Oncology (4 papers)Journal of Thoracic Oncology (4 papers)Annals of Surgical Oncology (3 papers)The Annals of Thoracic Surgery (3 papers)
- Partner nations
- ChinaUnited StatesGermany
In The Last Decade
Ke‐Neng Chen
100 papers receiving 4.1k citations
Ke‐Neng Chen's Hit Papers
Peers
Comparison fields: 5 of 83
- Pulmonary and Respiratory Medicine 2.3k
- Oncology 861
- Neurology 355
- Cancer Research 249
- Surgery 588
Countries citing papers authored by Ke‐Neng Chen
This map shows the geographic impact of Ke‐Neng Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ke‐Neng Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ke‐Neng Chen more than expected).
Fields of papers citing papers by Ke‐Neng Chen
This network shows the impact of papers produced by Ke‐Neng Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ke‐Neng Chen. The network helps show where Ke‐Neng Chen may publish in the future.
Co-authors
The 25 scholars most cited alongside Ke‐Neng Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 104 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer Hit paper breakdown → | 2023 | 711 |
| 2 | Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study Hit paper breakdown → | 2017 | 427 |
| 3 | Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer Hit paper breakdown → | 2024 | 238 |
| 4 | 2019 | 214 | |
| 5 | 2020 | 210 | |
| 6 | 2012 | 175 | |
| 7 | Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma Hit paper breakdown → | 2021 | 145 |
| 8 | Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2024 | 145 |
| 9 | 2018 | 122 | |
| 10 | 2019 | 92 | |
| 11 | 2005 | 85 | |
| 12 | 2002 | 82 | |
| 13 | 2017 | 76 | |
| 14 | 2021 | 65 | |
| 15 | 2018 | 59 | |
| 16 | 2023 | 59 | |
| 17 | 2018 | 58 | |
| 18 | 2014 | 53 | |
| 19 | 2012 | 47 | |
| 20 | 2016 | 45 |
About Ke‐Neng Chen
Ke‐Neng Chen is a scholar working on Pulmonary and Respiratory Medicine, Neurology, Oncology, Surgery and Cancer Research, having authored 104 papers that have together received 4.2k indexed citations. Recurring topics across this work include Lung Cancer Diagnosis and Treatment (27 papers), Esophageal Cancer Research and Treatment (24 papers), Myasthenia Gravis and Thymoma (20 papers), Lung Cancer Treatments and Mutations (15 papers), Cancer Immunotherapy and Biomarkers (9 papers), Sarcoma Diagnosis and Treatment (5 papers), Lung Cancer Research Studies (5 papers) and Cancer Genomics and Diagnostics (4 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (2.3k citations), Oncology (861 citations), Neurology (355 citations), Cancer Research (249 citations) and Surgery (588 citations). Ke‐Neng Chen has collaborated with scholars based in China, United States and Germany. Frequent co-authors include Shugeng Gao, Jonathan David Spicer, Moïshe Liberman, E. Eigendorff, Jing Liang Yang, Se‐Hoon Lee, Jamie E. Chaft, Steven M. Keller, Terufumi Kato and Heather A. Wakelee. Their work appears in journals such as Translational Lung Cancer Research, Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Surgical Oncology and The Annals of Thoracic Surgery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.